Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country.

"Everything we've seen happening over the last year or two in China goes in the

Read the full 440 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE